Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A vaccine comprising a first nucleic acid having a first nucleotide sequence with at least 90% sequence identity to SEQ ID No. 25 and a second nucleic acid having a second nucleotide sequence with at least 90% sequence identity to SEQ ID No. 23, and an acceptable pharmaceutical or veterinarily acceptable vehicle, wherein said first nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus.
2. The vaccine according to claim 1 , wherein said first nucleotide sequence is SEQ ID No. 25.
3. The vaccine according to claim 1 , wherein said second nucleotide sequence is SEQ ID No. 23.
4. The vaccine according to claim 1 , further comprising an adjuvant.
5. A vaccine comprising a first nucleic acid having a first nucleotide sequence with at least 95% sequence identity to SEQ ID No. 25 and a second nucleic acid having a second nucleotide sequence with at least 90% sequence identity to SEQ ID No. 23, and an acceptable pharmaceutical or veterinarily acceptable vehicle, wherein said first nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus.
6. The vaccine according to claim 5 , further comprising an adjuvant.
7. A vaccine comprising a first nucleic acid having a first nucleotide sequence with at least 90% sequence identity to SEQ ID No. 25 and a second nucleic acid having a second nucleotide sequence with at least 95% sequence identity to SEQ ID No. 23, and an acceptable pharmaceutical or veterinarily acceptable vehicle, wherein said first nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus.
8. The vaccine according to claim 1 , further comprising an adjuvant.
9. A vaccine comprising a first nucleic acid having a first nucleotide sequence with at least 95% sequence identity to SEQ ID No. 25 and a second nucleic acid having a second nucleotide sequence with at least 95% sequence identity to SEQ ID No. 23, and an acceptable pharmaceutical or veterinarily acceptable vehicle, wherein said first nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus.
10. The vaccine according to claim 9 , further comprising an adjuvant.
11. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 1 .
12. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 2 .
13. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 3 .
14. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 4 .
15. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 5 .
16. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 6 .
17. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 7 .
18. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 8 .
19. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 9 .
20. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of claim 10 .
21. A method of immunizing a mammal against piglet weight loss disease comprising:
(1) administering a first injection comprising:
(a) a plasmid comprising a first nucleic acid having a first nucleotide sequence with at least 90% sequence identity to SEQ ID No. 25;
(b) a plasmid comprising a second nucleic acid having a second nucleotide sequence with at least 90% sequence identity to SEQ ID No. 23, and
(c) an acceptable pharmaceutical or veterinarily acceptable vehicle,
wherein said first nucleic acid encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease circovirus;
(2) administering weeks after said first injection, a second and third injection, wherein said second injection comprises (a)-(c) of said first injection, and said third injection comprises host cells comprising (a)-(c) of said first injection.
22. The method of claim 21 , wherein the first and second nucleotide sequences are on different plasmids.
23. The method of claim 21 , wherein the first and second nucleotide sequences are on the same plasmid.
24. The method of claim 21 , wherein at least one of said plasmids further comprises a nucleic acid sequence encoding a therapeutic protein.
25. The method of claim 24 , wherein the therapeutic protein is granulocyte-macrophage colony stimulating factor (GMCSF).
26. The method of claim 21 , wherein the second and third injections are given five weeks after the first injection.
27. The method of claim 21 , wherein the first and second injections comprise 200 μg of plasmid DNA.
28. The method of claim 21 , wherein the first and second injections are administered intramuscularly.
29. The method of claim 21 , wherein the injections further comprise an adjuvant.
30. The method of claim 21 , wherein the adjuvant is AIF SEPPIC.
31. The method of claim 21 , wherein the third injection comprises 5×10 6 host cells.
32. The method of claim 21 , wherein said first nucleotide sequence is 95% identical to SEQ ID NO:25.
33. The method of claim 21 , wherein said second nucleotide sequence is 95% identical to SEQ ID NO:23.
34. The method of claim 21 , wherein said first nucleotide sequence is 95% identical to SEQ ID NO:25, and said second nucleotide sequence is 95% identical to SEQ ID NO:23.